Guardant Health (NASDAQ:GH) CEO Amirali Talasaz Sells 37,500 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 37,500 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $169.16, for a total transaction of $6,343,500.00. Following the completion of the transaction, the chief executive officer directly owned 37,500 shares of the company’s stock, valued at approximately $6,343,500. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The shares were sold at an average price of $150.79, for a total value of $17,638,207.88.
• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12.

Guardant Health Stock Performance

NASDAQ:GH opened at $163.18 on Tuesday. Guardant Health, Inc. has a one year low of $53.40 and a one year high of $176.58. The business’s 50-day simple moving average is $154.58 and its 200 day simple moving average is $119.07. The stock has a market cap of $21.90 billion, a price-to-earnings ratio of -46.76 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. During the same period in the prior year, the company posted ($0.44) EPS. The company’s revenue for the quarter was up 44.3% on a year-over-year basis. On average, equities research analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC bought a new position in Guardant Health during the 4th quarter worth $35,000. Parallel Advisors LLC boosted its holdings in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after acquiring an additional 219 shares during the period. Ascentis Independent Advisors acquired a new position in shares of Guardant Health during the first quarter valued at $38,000. Hollencrest Capital Management bought a new position in shares of Guardant Health during the first quarter worth about $41,000. Finally, EFG International AG bought a new position in shares of Guardant Health during the fourth quarter worth about $41,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GH. Stifel Nicolaus raised their price target on shares of Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Piper Sandler upped their price target on shares of Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. BTIG Research increased their price objective on shares of Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Morgan Stanley raised their price objective on shares of Guardant Health from $175.00 to $185.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Finally, Canaccord Genuity Group boosted their target price on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.